Beyond Binding: The Outcomes of Antibody-Dependent Complement Activation in Human Malaria

Dilini Rathnayake, Elizabeth H. Aitken and Stephen J. Rogerson*

Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia

Antibody immunity against malaria is effective but non-sterile. In addition to antibody-mediated inhibition, neutralisation or opsonisation of malaria parasites, antibody-mediated complement activation is also important in defense against infection. Antibodies form immune complexes with parasite-derived antigens that can activate the classical complement pathway. The complement system provides efficient surveillance for infection, and its activation leads to parasite lysis or parasite opsonisation for phagocytosis. The induction of complement-fixing antibodies contributes significantly to the development of protective immunity against clinical malaria. These complement-fixing antibodies can form immune complexes that are recognised by complement receptors on innate cells of the immune system. The efficient clearance of immune complexes is accompanied by complement receptor internalisation, abrogating the detrimental consequences of excess complement activation. Here, we review the mechanisms of activation of complement by alternative, classical, and lectin pathways in human malaria at different stages of the *Plasmodium* life cycle with special emphasis on how complement-fixing antibodies contribute to protective immunity. We briefly touch upon the action of anaphylatoxins, the assembly of membrane attack complex, and the possible reasons underlying the resistance of infected erythrocytes towards antibody-mediated complement lysis, relevant to their prolonged survival in the blood of the human host. We make suggestions for further research on effector functions of antibody-mediated complement activation that would guide future researchers in deploying complement-fixing antibodies in preventive or therapeutic strategies against malaria.

Keywords: malaria, immune complexes, classical complement pathway, infected erythrocytes, complement regulatory proteins, *Plasmodium falciparum* erythrocyte membrane protein 1

INTRODUCTION TO MALARIA

Malaria remains one of the major causes of severe morbidity and mortality globally. In 2019 alone, there were 229 million clinical episodes of malaria causing 0.4 million deaths. The most vulnerable groups include children under five years of age and pregnant women and the heaviest burden of disease is concentrated in sub-Saharan Africa (1). Clinical malaria presents as a febrile illness, that can progress to severe disease, causing death (2). Severe malaria often manifests as severe anaemia,
cerebral malaria or acute lung or kidney injury. Lung or kidney injury may lead to pulmonary oedema or renal failure, which is less common in children than adults [reviewed in (3)]. In pregnant women, infection in the placenta may cause adverse outcomes including abortion, stillbirth, intrauterine growth retardation, low infant birth weight, and neonatal death [reviewed in (4)]. Treatment strategies involve the use of artemisinin combination therapies, while vector control and effective surveillance are also important [reviewed in (5)].

In people living in malaria-endemic areas, immunity to malaria is gradually acquired following repeated exposure so that over time individuals become relatively protected from malaria and its complications [reviewed in (6)]. This naturally acquired immunity was demonstrated to be antibody-mediated, when antibodies transferred from apparently immune adults to young children with clinical malaria were able to reduce parasite densities (7).

The leading malaria vaccine candidate RTS,S induces antibodies to the circumsporozoite protein, and both naturally acquired and vaccine-induced antibodies fix complement and engage Fc receptors (8–10), discussed later.

The asexual replication of Plasmodium parasites within human erythrocytes is responsible for clinical symptoms of malaria. The parasite has a complex life cycle initiated by a Plasmodium-infected mosquito bite (see Figure 1 for life cycle of P. falciparum).

We focus on the importance of understanding the roles of antibody-mediated complement activation in these different stages of the Plasmodium life cycle, together with the mechanisms that parasites adopt to evade complement attack to promote their survival. A deeper understanding of antibody-mediated complement activation across the Plasmodium life cycle will provide insights into harnessing complement activation in antibody-mediated protection in malaria.

**COMPLEMENT ACTIVATION AND ITS ROLE IN MALARIA IMMUNITY**

**Introduction to the Complement System**

The complement system is a first line of defense against invading pathogens. It consists of both soluble and membrane-bound proteins, of which many are proteases that are proteolytically cleaved in a sequential cascade during activation [reviewed in (11, 12)]. These proteins can be deposited on the surface of pathogens or on host cells to produce a membrane attack complex (MAC) via three pathways, namely the classical, alternative, and mannose-binding lectin (MBL) [reviewed in (11)]. In malaria, the complement system may be activated in response to whole parasites or parasite-derived proteins in the host circulation [reviewed in (13)] (Figure 2).

The activation of complement is tightly regulated by both soluble and membrane-bound complement regulatory proteins (CRPs) that act at definitive points of the cascade and that are essential to prevent autologous complement attack (Figure 2) [reviewed in (14)]. The membrane-bound CRPs are...
constitutively expressed on the surface of cells including erythrocytes and cells within organs like the kidney, while the fluid-phase CRPs circulate in the plasma and are recruited onto the cell surface upon requirement [reviewed in (16)].

### Levels of Complement in Serum During Malaria

Alterations in the levels of complement in serum have been reported during malaria (17–22). The studies performed in a *P. lophurae* infected duck model showed decreased serum levels of initial complement proteins, C1, C2, and C4 during infection (23). Reduced levels of C4 in serum in simian malaria have been reported implicating classical complement activation (19). Rhesus monkeys infected with *P. coatneyi* showed decreased serum levels of initial complement proteins, C1, C2, and C4 during schizont rupture (24). Human studies showed reduced serum complement levels in patients with cerebral malaria compared to benign infection also indicating classical complement activation (17). Similarly, studies in malaria-infected pregnant women showed increased amounts of C1q, C3d, C4, and C9 in malaria-infected placentas compared to non-infected placentas (25), and deposition of IgG and C3 in some of the *P. falciparum*-infected placentas (26), although no association was shown between infection severity and the amount of complement deposited on the infected placentas. Genome-wide expression analyses showed an upregulation of C1q, C3, C5aR, and C3aR genes in the placentas of primigravid women with malaria compared to placentas of primigravid women without placental malaria (27), implying a role for classical complement activation in disease pathology.

Both the alternative and the classical complement pathways are activated in malaria, indicated by increased levels of alternative pathway derived components, Bb (a breakdown product of factor B) and classical pathway components like C4d (a split product of inactive C4b) as well as soluble C5b-C9 in natural *P. falciparum* infection (28). Complement activation is also regarded as one of the earliest immune responses against experimental *P. falciparum* infection and can be demonstrated when parasitaemia is still undetectable in peripheral blood (22). In studies performed in children with severe malarial anaemia and uncomplicated malaria,
the complement system is activated, but a higher level of complement consumption was observed in children with severe malarial anaemia compared to uncomplicated malaria (20).

The parasite components that directly activate complement in malaria include malarial antigens expressed on the surface of IEs (29), and the products of IE rupture like hematin (30). The antigens released by *P. falciparum* growing in culture including merozoites can activate all three pathways of complement, but they cause greatest activation of the alternative pathway (see Figure 2) (31).

The role of lectin complement pathway in malaria is not clearly demonstrated. MBL seems to recognise parasite proteins of *P. falciparum*-IEs (32, 33) and may activate lectin pathway.

Genetic studies also reveal a role of MBL protein in malaria. The concentration of MBL protein in serum is genetically determined and different haplotype variants of the MBL gene influence the circulating levels of MBL protein (34). In a study from Gabon, MBL gene polymorphisms were associated with reduced serum levels of MBL protein, and these mutations were present at a higher frequency in children with severe malaria compared to those with mild malaria, suggesting that low MBL levels might be a risk factor for severe malaria (35). This observation was further supported by another study from Ghana that showed low levels of MBL associated with the *mbl2* gene variant increased both susceptibility to *P. falciparum* infection and to severe malaria in young children (36).

By contrast, some studies were unable to show any associations between MBL polymorphisms with parasitaemia and severe disease. Multiple variant alleles of the *mbl2* gene that predicted low serum levels of MBL were not associated with infection or malaria severity in Ghanaian children (33), asymptomatic *P. falciparum* infection in Gabonese children (37), or clinical malaria in Gambian children (38). These discrepancies may be a result of the differences in study design as well as the disease manifestations, and age groups of children enrolled in each study. Taken together, all these studies highlight the possible importance of the lectin pathway in malaria severity, but further studies are needed to fully elucidate the role of MBL and its polymorphisms in malaria susceptibility.

### Antibodies Activate the Classical Complement Pathway in Malaria

Antigen-antibody immune complexes (ICs) activate complement *via* the classical pathway in malaria (reviewed in (39)). They are formed when antibodies bind malarial antigens circulating in plasma (Figure 3A) or expressed on the surface of sporozoites, merozoites, and IEs (Figure 3B). In individuals infected with malaria for the first time, ICs may first form approximately 10-14 days after infection, while in subsequent Plasmodium infections complement appears to be activated earlier (13).

The binding of globular head domains of the complement factor C1q with the antibody constant (Fc) domain regions of IgG hexamers or IgM binding antigen activates the classical complement pathway (40). The ability of IgG or IgM antibodies to activate the classical complement pathway depends on antibody isotype and subclass, with IgM-bound ICs having the highest ability to bind C1q and activate the classical pathway, while IgG4 has the lowest activity, and for the other IgG subclasses, the affinities for C1q are IgG3 > IgG1 > IgG2 [reviewed in (41)].

In the next section, we provide a brief overview of antibody-mediated complement fixation on different stages of *P. falciparum* within the human host. We discuss the mechanisms of clearance of the parasites *via* complement-mediated lysis that are brought about by activation of the classical complement pathway in the presence of ICs. We also review the influence of intrinsic and extrinsic properties of both host and parasite that could have a potential impact on complement-dependent lysis of different parasitic stages.

### Antibody-Dependent Complement Fixation on Different Parasitic Stages

**Sporozoites**

After injection by the mosquito, *Plasmodium* spp. sporozoites enter the blood vessels and move through the circulation and

---

**FIGURE 3** | The immune complexes (ICs) are formed when antigens and antibodies unite. They can be formed when the circulating plasmodial antigens cross-link with antibodies in the plasma (A) or antibodies can bind with the antigens expressed on the surface of sporozoites, merozoites, or IEs as shown in (B). The circulating ICs (as in A) can also get deposited on the surface of the parasite or on other cells like uninfected erythrocytes, promoting complement deposition on host cell surfaces. These ICs recruit C1q when the globular head domains of C1q bind with the Fc constant region (B) of ICs to activate a cascade of downstream events of the classical complement pathway.
invade hepatocytes, where they divide to produce merozoites which are released to initiate blood-stage infection (Figure 1) [reviewed in (42)]. Targeting sporozoites is potentially an efficient way of preventing malaria as only a small number of sporozoites are injected by the female mosquito during a blood meal.

Studies in murine models have shown that the passive transfer of monoclonal antibodies against the sporozoites of *P. yoelii* inhibited liver infection and the progression to blood-stage infection (43, 44) while in humans, antibodies against *P. falciparum* sporozoites inhibited the movement of sporozoites into hepatocytes in vitro (9).

Recent in vitro studies conducted in humans showed that these naturally-acquired antibodies against sporozoites of *P. falciparum* can fix complement on the sporozoite surface and are predominantly of cytophilic subclasses, immunoglobulin 1 (IgG1) and IgG3 (9). The hepatocyte transversal inhibitory activity of the naturally acquired anti-sporozoite antibodies was substantially enhanced in the presence of complement, resulting in fixation of C1q on sporozoites and causing their death (9).

Studies show that immunisation with live-attenuated sporozoites of *P. falciparum* can induce sporozoite-specific IgG and IgM antibodies that can fix complement on the sporozoite surface. These antibodies can inhibit sporozoite traversal and invasion into hepatocytes and enhance sporozoite membrane permeability, resulting in sporozoite lysis (45, 46). Similarly, the RTSS vaccine is based on the major circumsporozoite protein (CSP) on *P. falciparum* sporozoites, and anti-CSP antibodies are induced following RTSS vaccination that are functional and fix complement factor C1q (47).

In summary, induction of complement-fixing antibodies against sporozoite antigens via natural exposure and vaccination can inhibit sporozoite transversal into liver hepatocytes leading to their lysis and death (9), and these antibodies are associated with protection from clinical malaria (9, 46).

**Merozoites**

Studies have identified merozoite surface proteins (MSP) such as MSP1, MSP3, and apical membrane antigen-1 [reviewed in (48)], as important targets of protective antibodies, particularly of type IgG (49). The antibodies targeting merozoites limit parasite replication and inhibit invasion of erythrocytes.

Both naturally acquired (50) and vaccine-induced (50, 51) human antibodies against merozoites promote C1q complement deposition on the merozoite surface and activation of the classical complement pathway, inhibiting merozoite invasion and lysing merozoites (50). A longitudinal cohort study performed in older children showed strong associations between complement-fixing antibodies against MSP1 and MSP2 with protection from clinical malaria and high parasitaemia (50). This observation is further supported by a similar study in malaria-exposed children (52) that showed that complement-fixing antibodies against merozoite antigens were a strong predictor of protection against malaria in children.

**Gametocyte-Infected Erythrocytes**

Gametocyte-IEs are the infective stages of the parasite that enable transmission of infection from human to mosquito [reviewed in (53)]. There is limited recognition of gametocyte-IEs by naturally acquired antibodies within the human host and this low level of recognition may facilitate the evasion of host immunity and transmission of infection to the mosquito (54).

When an Anopheles mosquito takes a blood meal, host serum components like complement proteins and antibodies are taken in along with the gametocyte-IEs (Figure 1) [reviewed in (53)]. In the mosquito midgut, the gametocytes emerge from the erythrocytes, and are exposed to complement proteins and antibodies [reviewed in (53)].

Most studies on immunity to *P. falciparum* sexual stages revolve around the major gametocyte surface antigen, Pf230 [reviewed in (55)]. Previous studies showed that the transmission blocking activities of monoclonal antibodies against Pf230 were complement dependent (56), and in vitro complement-mediated lysis of gametes by immune sera is associated with antibodies towards Pf230 (57). But in membrane feeding assays, the transmission blocking activity of immune sera has yet to be shown to be complement dependent (58). Pf230 is a leading candidate for transmission-blocking vaccines (59), and is likely a major antigenic target for complement-fixing antibodies.

**Infected Erythrocytes**

The clinical symptoms of malaria are attributable to blood-stage infection. Some of the major targets of acquired immunity to blood-stage infection are the surface antigens on *P. falciparum*-IEs (60).

Parasite antigens on the surface of IEs play a major role in the pathology of severe malaria via parasite sequestration leading to cytoadhesion of IEs to vascular endothelium [reviewed in (61)] or syncytiotrophoblast of the placenta (62). These surface antigens can undergo antigenic variations (63) and are known as variant surface antigens (VSA) (64). The dominant VSAs that are expressed on the surface of IEs are the *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) family of proteins (65).

The surface of trophozoite-IE of *P. falciparum* is a target for antibody-dependent complement activation (29). In the presence of immune sera the classical complement pathway was activated as indicated by formation of complexes of C1s and C1 inhibitor, measured by ELISAs, although antibody-mediated lysis of IEs was not observed visually (29). Spectrometric quantification of the changes in optical absorbance induced by the release of haemoglobin serves as a better option (66).

Later, Weisner et al. showed that the complement cascade can be activated on the surface of IEs, detecting immunoglobulins, C3, C4, and C9 on the surface of IEs (but not uninfected erythrocytes) incubated with immune sera via western blot analyses (67). However, they failed to observe IE lysis by classical complement activation in the presence of immune sera suggesting that IEs are resistant to complement-mediated lysis, discussed in more detail in section 5.
Notwithstanding the resistance of antibody-opsonised IEs to complement-mediated lysis, IEs are susceptible to other mechanisms of antibody-mediated removal that are briefly discussed here. Previous studies have shown that antibody-opsonised IEs are cleared by monocytes (68, 69) and neutrophils (70) by cellular phagocytosis. Antibody-opsonised IEs can also activate NK cells, which resulted in lysis of IEs and inhibition of parasite growth (71).

COMPLEMENT ACTIVATION AND DISEASE OUTCOMES

Mechanisms of Immune Complex Clearance

Under normal physiological conditions, the ICs are efficiently cleared by a functional complement system preventing excess deposition of complement that brings detrimental effects to the host [reviewed in (11)]. The complement receptor 1 (CR1) on the surface of macrophages, B cells, neutrophils, dendritic cells, and erythrocytes in humans can recognise complement fragments C3b, iC3b, and C4b that are bound with ICs [reviewed in (11)]. CR1 binds, transports, and endocytoses C3b-bearing ICs to remove them from circulation [reviewed in (14)]. Additionally, the complement receptor 3 (CR3 or CD11b/CD18 complex) on the surface of leukocytes is involved in C3b-mediated opsonic phagocytosis by monocytes and neutrophils and plays a role in clearance of C3b-containing ICs [reviewed in (14)]. The Fc receptors of innate immune cells like neutrophils and monocytes can directly bind to the Fc domain of the ICs also promoting antibody-mediated opsonic phagocytosis (72).

Complement Activation in the Pathogenesis of Malaria

Mice infected with *P. yoelii* showed a downregulation of the level of expression of CR1 on monocytes or macrophages, a similar though less pronounced downregulation was reported in patients infected with *P. falciparum* and *P. vivax* compared to non-infected controls (73). Decreased CR1 expression on monocytes or macrophages in the mice was also associated with inhibited uptake of immune complexes and was also seen following exposure to lipopolysaccharide (73). Inflammation may contribute to decreased CR1 expression, which then leads to impaired ICs clearance in malaria, and possibly to disease as ICs are associated with increased disease severity (74). But the contribution of ICs to malaria pathogenesis is not fully known.

Both IgG and complement are shown to be deposited on the surface of uninfected erythrocytes in severe malarial anaemia (75, 76). Complement deposition promotes erythropagocytosis of IC-deposited erythrocytes via CR1 on macrophage surface (77). In *Plasmodium* infection, erythropagocytosis by macrophages seems complement-dependent (78), a possible mechanism for severe malarial anaemia not broadly discussed here (see Box 1).

Other than erythropagocytosis, erythrocytes with C3b-containing ICs are taken up by splenic reticuloendothelial cells. This may lead to stripping off of the CR1 from the erythrocyte surface (76, 79, 80). CR1-deficient erythrocytes are recirculated and are susceptible to complement attack, implicating complement deposition as a driver of severe malarial anaemia. Among heavily malaria-exposed Gambian children, about half developed a positive direct antiglobulin (Coombs) test (81). IgG was eluted from the surface of their uninfected erythrocytes, and in many cases it was shown to recognise schizonts (82), although the antigen specificity of the antibodies bound to uninfected erythrocytes has not been studied in detail. More recent studies [reviewed in (83)] confirm the deposition of IgG and C3 on these cells. The antibodies are postulated to be immunologically unrelated to the uninfected erythrocytes (81).

Complement activation generates C5a via the cleavage of C5, by C5 convertase (see Figure 2 for complement pathway). C5a is a potent inflammatory mediator (anaphylatoxin) that is readily cleared from plasma via receptor internalisation under normal physiological conditions [reviewed in (84)]. The ligation of C5 with C5a receptors (CD88 and C5L2) on innate immune cells promotes a cascade of conventional inflammatory events including increased leukocyte extravasation, neutrophil chemotaxis, degranulation, delayed apoptosis, phagocytosis, oxidative burst, and the activation of vascular endothelial cells to upregulate the expression of cell adhesion molecules [reviewed in (84)].

C5a is implicated in the pathogenesis of cerebral malaria (85) and placental malaria (86, 87). C5a is increased in women with placental malaria (87) and elevated C5a was associated with increased risk of birth of ‘small-for-gestational-age’ babies (86). Blocking C5a in a murine model of placental malaria resulted in improved placental and foetal development (86). Murine models have also highlighted a possible role for C5a in cerebral malaria as C5 deficient mice or those treated with antibodies blocking C5a and its receptor respectively did
not develop and could be rescued from cerebral malaria (85). Though there is some evidence for a role of the inflammatory complement C5a protein in disease, the anti-C5 monoclonal antibody eculizumab has not been studied in malaria (see Box 1).

The inflammatory effector functions mediated by the release of C5a in response to infection and the C3b-mediated opsonic phagocytosis of IEs (and/or other parasite stages, such as sporozoites, merozoites, and intraerythrocytic gametocytes) by innate immune cells are not discussed in detail in this review.

**MECHANISMS OF EVASION OF COMPLEMENT-MEDIATED LYSIS BY PLASMODIUM IEs**

Irrespective of the exposure of blood-stage parasites to serum complement over a relatively prolonged asexual blood-stage (Figure 1) (88), the IEs seem to be broadly resistant to complement-mediated lysis (67).

One reason why the IEs are resistant to complement-mediated lysis may be that the IEs may have low number of target sites for antibody-binding and complement activation. If this is below a certain threshold, even an excess of antigen-specific antibodies and serum complement may not activate the classical complement pathway (Figure 4A) (89).

Membrane-bound CRPs that act at different phases of the complement cascade tightly regulate complement activation [reviewed in (14)]. These include CD46 or membrane cofactor protein (MCP); CR1 which targets and cleaves C3 convertase; CD55 or decay accelerating factor (DAF) which accelerates the decay of both C3 and C5 convertase (90); and CD59 which acts on the terminal complement pathway (see Figure 2), targeting C5b-C9 to inhibit the assembly of MAC (90). Interestingly, the IEs appear to have high expression of CD59 that makes them resistant to complement mediated destruction (Figure 4B) (67).

In addition to the membrane-bound CRPs, the *P. falciparum*-IEs also utilise soluble complement factors like factor I (FI) and factor H (FH) (Figure 4B) to evade complement mediated lysis. FH utilises factor I for recruiting FH-related protein FHL-1 onto the schizont surface to inactivate C3b and regulates alternative complement activation in response to the rupture of IEs (91–93).

In an ex vivo study of subjects with severe malaria anaemia, the levels of expression of CRPs were lower on uninfected erythrocytes than on IEs (94). This loss of CRPs on uninfected erythrocytes in severe malaria anaemia was not associated with changes in complement-fixing cytophilic antibodies or serum.
markers of complement activation (as measured by the serum levels of C3a and C5a) (94). High levels of CRPs on IEs may help protect parasites from complement-mediated damage even in the presence of complement-fixing antibodies (94) and even when the terminal complement complexes are deposited on the erythrocyte surface (67).

A recent study assessed the classical complement activation by PfEMP1-specific human IgG using recombinant PfEMP1 by ELISAs and native PfEMP1 on the surface of IEs by flow cytometry (89). The PfEMP1-specific antibodies were unable to activate classical complement pathway by binding to the native PfEMP1 expressed on the surface of IEs (89), but when they bound to recombinant PfEMP1, they activated the classical complement pathway as measured by the elevated levels of C1q, C3, and C4. The authors hypothesised that the knob-restricted expression of native PfEMP1 protein on the IE surface may provide an evolutionary advantage to the parasite to evade classical complement attack (89). The knobs are nanoscale protrusions of the erythrocyte membrane (95) and enable anchorage of PfEMP1 to the surface of IEs (61). The knob-restricted expression of PfEMP1 may hinder the interaction between PfEMP1 and IgG, which may restrict the formation of IgG hexamers for C1q recruitment (40) (Figure 4C).

Most of the studies discussed previously highlighted that complement fixing antibodies on IEs were of type IgG (29), especially the subclasses, IgG1 and IgG3 (67). A recent study assessed the complement activation by nonimmune IgM when bound to PfEMP1 on IEs (Figure 4D) (96). The binding of IgM to PfEMP1 did not result in complement-mediated lysis because C1q seemed to compete for the same binding pocket on IgM where PfEMP1 is already bound. The interaction between IgM and PfEMP1 prevents C1q deposition and changes the conformation of PfEMP1 to augment PfEMP1-mediated parasite interactions with host receptors for its sequestration and survival (96).

The above reasons seem to contribute to the lack of lysis of IEs by the classical pathway of complement.

FUTURE DIRECTIONS AND CONCLUDING REMARKS

Some evidence (9) suggests that ability to fix complement is an independent correlate of ability of sera to kill sporozoites. Passive transfer studies of a modified monoclonal antibody against PfRh5 (P. falciparum reticulocyte homologue 5) indicate that neutralising antibody alone requires high titres (97), indicating a role for Fc-mediated antibody function. This may not, however, be directly attributable to complement fixation as studies of vaccine-induced immunity suggested that NK cell and Fc receptor receptor engagement rather than complement fixation were independent correlates of protection (10).

Despite such recent improvements in understanding of antibody-mediated complement interactions in protective immunity to malaria, the following gaps also should be addressed as priorities for future research (Box 1).

In this review, we summarise antibody-dependent complement activation by different stages of parasites during P. falciparum infection. Studies show that the inhibitory effect of antibodies directed against surface proteins of sporozoites (e.g., CSP, merozoites (e.g., MSP119), and sexual stages of P. falciparum (e.g., Pfs230) can be greatly augmented by the presence of complement. The binding of C1q to IgG-opsonised merozoites and sporozoites has shown to be associated with protective immunity in malaria. We also emphasise that IEs are resistant to complement mediated lysis in comparison to other parasitic stages. This may be due to some intrinsic properties of IEs, including the expression of complement regulatory proteins, an insufficient number of antigenic sites as targets for antibody binding, and the orientation of antigens on the parasite surface for restricted antibody binding for complement deposition. The attempts made to evaluate the underlying mechanisms of antibody-mediated complement activation during malaria will provide a deeper understanding of the processes that mediate complement-mediated protection and/or evasion.

AUTHOR CONTRIBUTIONS

DR gathered papers, organised, and drafted the review. Both EA and SR provided intellectual feedback, critically revised, and approved the final manuscript for submission. All authors contributed to the article and approved the submitted version.

FUNDING

DR is supported by the Melbourne Research Scholarship from the University of Melbourne and Miller Foundation Top-up Scholarship. The work of EA and SR is supported by grants from the National Health and Medical Research Council of Australia (GNT1092789 and GNT1143946), and by the Centre for Research Excellence in Malaria Elimination (GNT1134989).

ACKNOWLEDGMENTS

All the images were created with BioRender.com.

REFERENCES

1. World Health Organization. World Malaria Report 2020. In: 20 Years of Global Progress and Challenges. Geneva: World Health Organization. (2020).

2. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to Malaria: More Questions Than Answers. Nat Immunol (2008) 9(7):725–32. doi: 10.1038/nl.205

3. Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet (2018) 391:1608–21. doi: 10.1016/S0140-6736(18)30324-6
45. Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, et al. Immunization of Malaria-Preexposed Volunteers With PISPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies. *J Infect Dis* (2018) 217(10):1569–78. doi: 10.1093/infdis/jiy108
46. Behet MC, Kurtovic L, van Gemert GJ, Haukes CM, Siebelink-Stoter R, Graumans W, et al. The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization With Plasmodium Falciparum Malaria Sporozoites. *Infect Immun* (2018) 86(7):1–15. doi: 10.1128/IAI.00920-17
47. Kurtovic L, Agius PA, Feng G, Drew DR, Ubillos I, Sacarlal J, et al. Induction and Decay of Functional Complement-Fixing Antibodies by the RTS,S Malaria Vaccine in Children, and a Negative Impact of Malaria Exposure. *BMC Med* (2019) 17(1):1–14. doi: 10.1186/s12916-019-1277-x
48. Cowman AF, Crabb BS. Invasion of Red Blood Cells by Malaria Parasites. *Cell* (2006) 124:755–66. doi: 10.1016/j.cell.2006.02.006
49. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoep B, et al. Antibody-Dependent Complement Activation in Malaria. *Nat Commun* (2014) 5:4632. doi: 10.1038/ncomms5632
50. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Targets of Antibodies Against Plasmodium Falciparum-Infected Erythrocytes in Malaria Immunity. *J Clin Invest* (2012) 122(9):3227–38. doi: 10.1172/JCI62182
51. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJI, et al. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Efficiently Than Other Monocyte Subsets, and Require CD16 and Complement to do So. *BMC Med* (2015) 13(1):1–14. doi: 10.1186/s12916-015-0391-7
52. Arora G, Hart GT, Manzella-lapeira J, Doritchamou JYA, Narum DL, Thomas LM, et al. NK Cells Inhibit Plasmodium Falciparum Growth in Red Blood Cells Via Antibody-Dependent Cellular Cytotoxicity. *Elife* (2018) 7:1–20. doi: 10.7554/eLife.36806
53. Fernandez-Arias C, Lopez JP, Nikolae J, Bautista-ojeda MD, Branch O, et al. Malaria Inhibits Surface Expression of Complement Receptor 1 in Monocytes/Macrophages, Causing Decreased Immune Cell Internalization. *J Immunol* (2013) 193:3633–72. doi: 10.4049/jimmunol.1103812
54. Thomas BN, Diallo DA, Noumi GT, Moulds JM. Circulating Immune Complex Levels are Associated With Disease Severity and Seasonality in Children With Malaria From Mali. *Biomark Insights* (2012) 7:81–6. doi: 10.4137/BML.2012.35023
55. Dietz V, Winful M, Murphy H, Nosten F, et al. Human Monocytes Are Efficiently Complement-Dependent Receptor Transferred to Acceptor Phagocytic Cells? *Mol Immunol* (1999) 36:827–35. doi: 10.1016/S0161-5890(99)00103-0
56. Fernandez-Arias C, Lopez JP, Nikolae J, Bautista-ojeda MD, Branch O, et al. Malaria Inhibits Surface Expression of Complement Receptor 1 in Monocytes/Macrophages, Causing Decreased Immune Cell Internalization. *J Immunol* (2013) 193:3633–72. doi: 10.4049/jimmunol.1103812
57. Thomas BN, Diallo DA, Noumi GT, Moulds JM. Circulating Immune Complex Levels are Associated With Disease Severity and Seasonality in Children With Malaria From Mali. *Biomark Insights* (2012) 7:81–6. doi: 10.4137/BML.2012.35023
58. Dietz V, Winful M, Murphy H, Nosten F, et al. Human Monocytes Are Efficiently Complement-Dependent Receptor Transferred to Acceptor Phagocytic Cells? *Mol Immunol* (1999) 36:827–35. doi: 10.1016/S0161-5890(99)00103-0
59. Rathiya et al. Antibody-Dependent Complement Activation in Malaria
Susceptibility to Severe Malaria. J Infect Dis (2004) 190(6):1183–91. doi: 10.1086/423140
80. Stout JA, Odindao AO, Owuor BO, Mibe EK, Opollo MO, Waitumbi NJ. Loss of Red Blood Cell–Complement Regulatory Proteins and Increased Levels of Circulating Immune Complexes are Associated With Severe Malarial Anemia. J Infect Dis (2003) 187(3):522–5. doi: 10.1086/367712
81. Facer CA, Bray RS, Brown J. Direct Coombs Antiblobulin Reactions in Gambian Children With Plasmodium Falciparum Malaria I. Incidence Class Specificity Clin Exp Immunol (1979) 35:119–27.
82. Facer CA. Direct Coombs Antiblobulin Reactions in Gambian Children With Plasmodium Falciparum Malaria II. Specificity Erythrocyte-Bound IgG Clin Exp Immunol (1980) 39:279–88.
83. Stout JA. Complement Receptor 1 and Malaria. Cell Microbiol (2011) 13 (10):1441–50. doi: 10.1111/j.1462-5822.2011.01468.x
84. Wood AJT, Vassallo A, Summers C, Chilvers ER, Conway-Morris A. C5a Anaphylatoxin and its Role in Critical Illness-Induced Organ Dysfunction. Eur J Clin Invest (2018) 48(12):e13028. doi: 10.1111/ect.13028
85. Patel SN, Berghout J, Lovegrove FE, Ayi K, Conroy A, Serghides L, et al. C5 Deficiency and C5a or C5aR Blockade Protects Against Cerebral Malaria. J Exp Med (2008) 205(5):1133–43. doi: 10.1084/jem.20072248
86. Conroy AL, Silver KL, Zhong K, Rennie M, Ward P, Sarma JV, et al. Complement Activation and the Resulting Placental Vascular Insufficiency Drives Fetal Growth Restriction Associated With Placental Malaria. Cell Host Microbe (2013) 13(2):215–26. doi: 10.1016/j.chom.2013.01.010
87. Conroy A, Serghides L, Finney C, Owino SO, Kumar S, Gowda DC, et al. C5a Enhances Dysregulated Inflammatory and Angiogenic Responses to Malaria in Vitro: Potential Implications for Placental Malaria. PLoS One (2009) 4(3): e4953. doi: 10.1371/journal.pone.0004953
88. David PH, Hommel M, Miller LH, Udeinya IJ, Oligino LD. Parasite Sequestration in Plasmodium Falciparum Malaria: Spleen and Antibody Modulation of Cytodherence of Infected Erythrocytes. Proc Natl Acad Sci (1983) 80(16):5075–9. doi: 10.1073/pnas.80.16.5075
89. Larsen MD, Quintana M del P, Ditlev SB, Bayarri-Olmos R, Ofori MF, Hviid L, et al. Evasion of Classical Complement Pathway Activation on Plasmodium Falciparum-Infected Erythrocytes Opsonized by PIEMP1-Specific IgG. Front Immunol (2019) 9(Jan):1–10. doi: 10.3389/fimmu.2018.03088
90. Sarma JV, Ward PA. The Complement System. Cell Tissue Res (2011) 343 (1):227–35. doi: 10.1007/s00441-010-1034-0
91. Rosa TFA, Flammersfeld A, Ngwa CJ, Kiesow M, Fischer R, Zipfel PF, et al. The Plasmodium Falciparum Blood Stages Acquire Factor H Family Proteins to Evade Destruction by Human Complement. Cell Microbiol (2016) 18 (4):573–90. doi: 10.1111/cmi.12535
92. Reiss T, Rosa TF de A, Blaesius K, Bobbert RP, Zipfel PF, Skerka C, et al. Cutting Edge: Fhr-1 Binding Impairs Factor H–Mediated Complement Evasion by the Malaria Parasite Plasmodium Falciparum. J Immunol (2018) 201(12):3497–502. doi: 10.4049/jimmunol.1800662
93. Kennedy AT, Schmidt CQ, Thompson JK, Weiss GE, Taechalertpaisarn T, Gibson PR, et al. Recruitment of Factor H as a Novel Complement Evasion Strategy for Blood-Stage Plasmodium Falciparum Infection. J Immunol (2016) 196(3):1239–48. doi: 10.4049/jimmunol.1501581
94. Oyong DA, Kenangalem E, Poespoprodjo JR, Beeson JG, Anstey NM, Price RN, et al. Loss of Complement Regulatory Proteins on Uninfected Erythrocytes in Vivax and Falciparum Malaria Anemia. JCI Insight (2018) 3 (22):1–11. doi: 10.1172/jci.insight.124854
95. Nagao E, Kaneko O, Dvorak JA. Plasmodium Falciparum-Infected Erythrocytes: Qualitative and Quantitative Analyses of Parasite-Induced Knobs by Atomic Force Microscopy. J Struct Biol (2000) 130:34–44. doi: 10.1006/jsbi.2000.4236
96. Akhouari RR, Goel S, Furusho H, Skoglund U, Wahlgren M. Architecture of Human IgM in Complex With P. Falciparum Erythrocyte Membrane Protein 1 Cell Rep (2016) Feb 14(4):723–36. doi: 10.1016/j.celrep.2015.12.067
97. Douglas AD, Baldeviano GC, Jin J, Miura K, Doud A, Zemonos ZA, et al. A Defined Mechanistic Correlate of Protection Against Plasmodium Falciparum Malaria in non-Human Primates. Nat Commun (2019) 10(1953):1–8. doi: 10.1038/s41467-019-09894-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Rathnayake, Aitken and Rogerson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.